SFRP2 and Miyoshi myopathy: sFRP-2, has been found to be constitutively produced by MM cells of patients with advanced bone lesions, and the removal of sFRP-2 from MM cell-conditioned media restored osteoblast differentiation and maturation supporting sFRP-2’s role in impaired bone formation [29, 30].